Erratum to "Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity" [Clin. Immunol. 118 (2006) 42-50] (DOI:10.1016/j.clim.2005.08.017);Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity

Clinical Immunology

Volumn 118, Issue 1, 2006, Pages 42-50

  Barbosa, Maria D F S ^a   Vielmetter, Jost ^a   Chu, Seung ^a   Smith, David D ^b   Jacinto, Jonathan ^a  

^a Xencor Inc   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Allele; Antibody; Epitope; HLA type; Immunogenicity; Interferon beta; MHC class II; Multiple sclerosis; T cells

Indexed keywords

ANTIBODY; BETA INTERFERON; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

ALLELE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; HAPLOTYPE; HUMAN; HUMAN CELL; IMMUNOGENICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 29444451997     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.01.013     Document Type: Erratum

References (45)

1. D.J. Kuter, and C.G. Begley Recombinant human thrombopoietin: basic biology and evaluation of clinical studies Blood 100 2002 3457 3469
2. E. Koren, L.A. Zuckerman, and A.R. Mire-Sluis Immune responses to therapeutic proteins in humans-Clinical significance, assessment and prediction Curr. Pharm. Biotechnol. 3 2002 349 360
3. K.R. Carson, A.M. Evens, C.L. Bennett, and S. Luminari Clinical characteristics of erythropoietin-associated pure red cell aplasia Best Pract. Res. Clin. Haematol. 18 2005 467 472
4. C.H. Polman, and B.M. Uitdehaag New and emerging treatment options for multiple sclerosis Lancet Neurol. 2 2003 563 566
5. M. Boes, and H.L. Ploegh Translating cell biology in vitro to immunity in vivo Nature 430 2004 264 271
6. A. Braun, L. Kwee, M.A. Labow, and J. Alsenz Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice Pharm. Res. 14 1997 1472 1478
7. R.N. Germain The biochemistry and cell biology of antigen presentation by MHC class I and class II molecules. Implications for development of combination vaccines Ann. N. Y. Acad. Sci. 754 1995 114 125
8. H.O. McDevitt The role of MHC class II molecules in susceptibility and resistance to autoimmunity Curr. Opin. Immunol. 10 1998 677 681
9. E.J. McMahon, S.L. Bailey, C.V. Castenada, H. Waldner, and S.D. Miller Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis Nat. Med. 11 2005 335 339
10. M. Greter, F.L. Heppner, M.P. Lemos, B.M. Odermatt, N. Goebels, T. Laufer, R.J. Noelle, and B. Becher Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis Nat. Med. 11 2005 328 334
11. D.A. Hafler, J.M. Slavik, D.E. Anderson, K.C. O'Connor, P. De Jager, and C. Baecher-Allan Multiple sclerosis Immunol. Rev. 204 2005 208 231
12. D.M. Carrington, A. Auffret, and D.E. Hanke Polypeptide ligation occurs during post-translational modification of concanavalin A Nature 313 1985 64 67
13. H. Paulus Protein splicing and related forms of protein autoprocessing Annu. Rev. Biochem. 69 2000 447 496
14. K. Hanada, J.W. Yewdell, and J.C. Yang Immune recognition of a human renal cancer antigen through post-translational protein splicing Nature 427 2004 252 256
15. F. Gilli, F. Marnetto, M. Caldano, A. Sala, S. Malucchi, A. Di Sapio, M. Capobianco, and A. Bertolotto Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis J. Neuroimmunol. 158 2005 195 203
16. S. Malucchi, A. Sala, F. Gilli, R. Bottero, A. Di Sapio, M. Capobianco, and A. Bertolotto Neutralizing antibodies reduce the efficacy of bIFN during treatment of multiple sclerosis Neurology 62 2004 2031 2037
17. P.S. Sorensen, C. Ross, K.M. Clemmesen, K. Bendtzen, J.L. Frederiksen, K. Jensen, O. Kristensen, T. Petersen, S. Rasmussen, M. Ravnborg, E. Stenager, and N. Koch-Henriksen Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis Lancet 362 2003 1184 1191
18. A. Bertolotto, S. Malucchi, E. Milano, A. Castello, M. Capobianco, and R. Mutani Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations Immunopharmacology 48 2000 95 100
19. L. Durelli Is multiple sclerosis a disease that requires frequent beta interferon dosing? J. Neurol. 251 Suppl. 4 2004 IV13 IV24
20. A. Bertolotto, F. Deisenhammer, P. Gallo, and P. Solberg Sorensen Immunogenicity of interferon beta: differences among products J. Neurol. 251 Suppl. 2 2004 II15 II24
21. M. Stickler, A.M. Valdes, W. Gebel, O.J. Razo, N. Faravashi, R. Chin, N. Rochanayon, and F.A. Harding The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta Genes Immun. 5 2004 1 7
22. V.P. Yeung, J. Chang, J. Miller, C. Barnett, M. Stickler, and F.A. Harding Elimination of an immunodominant CD4+ T cell epitope in human IFN-b does not result in an in vivo response directed at the subdominant epitope J. Immunol. 172 2004 6658 6665
23. W. Jennes, L. Kestens, D.F. Nixon, and B.L. Shacklett Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15-The Amplispot assay J. Immunol. Methods 270 2002 99 108
24. S.J. Brett, J. Blau, C.M. Hughes-Jenkins, J. Rhodes, F.Y. Liew, and J.P. Tite Human T cell recognition of influenza A nucleoprotein. Specificity and genetic restriction of immunodominant T helper cell epitopes J. Immunol. 147 1991 984 991
25. R. Busch, C.M. Hill, J.D. Hayball, J.R. Lamb, and J.B. Rothbard Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding J. Immunol. Methods 147 1991 1292 1298
26. D. Valmori, A. Sabbatini, A. Lanzavecchia, G. Corradin, and P.M. Matricardi Functional analysis of two tetanus toxin universal T cell epitopes in their interaction with DR1101 and DR1104 alleles J. Immunol. Methods 152 1994 2921 2929
27. B.M. Diethelm-Okita, D.K. Okita, L. Banaszak, and B.M. Conti-Fine Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins J. Infect. Dis. 181 2000 1001 1009
28. A.R. Mire-Sluis, Y.C. Barrett, V. Devanarayan, E. Koren, H. Liu, M. Maia, T. Parish, G. Scott, G. Shankar, E. Shores, S.J. Swanson, G. Taniguchi, D. Wierda, and L.A. Zuckerman Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products J. Immunol. Methods 289 2004 1 16
29. A.R. Pachner An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients Neurology 61 2003 1444 1446
30. R. Busch, G. Strang, K. Howland, and J.B. Rothbard Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces Int. Immunol. 2 1990 443 451
31. R. Omiya, C. Buteau, H. Kobayashi, C.V. Paya, and E. Celis Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope J. Immunol. 169 2002 2172 2179
32. R.A. Fisher The logic of inductive inference J. R. Stat. Soc., A 98 1935 39 54
33. R.G. O'Brien A general ANOVA method for robust tests of additive models for variances J. Am. Stat. Assoc. 74 1979 877 880
34. O.A. Khan, Q. Xia, C.T. Bever Jr., K.P. Johnson, H.S. Panitch, and S.S. Dhib-Jalbut Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration Neurology 46 1996 1639 1643
35. E. Yunis, A. Begovich, Z. Awdeh, L.A. Baxter-Lowe, H. Noreen, B. Schmeckpeper, T. Spalding, T.M. Williams, J. Hegland, and M. Salazar HLA class II allele frequencies in unrelated donor bone marrow transplantation Hum. Immunol. 47 1996 105
36. W. Klitz, M. Maiers, S. Spellman, L.A. Baxter-Lowe, B. Schmeckpeper, T.M. Williams, and M. Fernandez-Vina New HLA haplotype frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans Tissue Antigens 62 2003 296 307
37. O. Olerup, and J. Hillert HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation Tissue Antigens 38 1991 1 15
38. K. Novak, and S. Grossman Research news: new kid on the block Nat. Med. 9 2003 172
39. S. Tangri, B.R. Mothe, J. Eisenbraun, J. Sidney, S. Southwood, K. Briggs, J. Zinckgraf, P. Bilsel, M. Newman, R. Chesnut, C. Licalsi, and A. Sette Rationally engineered therapeutic proteins with reduced immunogenicity J. Immunol. 174 2005 3187 3196
40. G. Bonomi, F. Moschella, M.N. Ombra, G. Del Pozzo, C. Granier, P. De Berardinis, and J. Guardiola Modulation of TCR recognition of MHC class II/peptide by processed remote N- and C-terminal epitope extensions Hum. Immunol. 61 2000 753 763
41. H. Kropshofer, S. Spindeldreher, T.A. Rohn, N. Platania, C. Grygar, N. Daniel, A. Wolpl, H. Langen, V. Horejsi, and A.B. Vogt Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes Nat. Immunol. 3 2002 61 68
42. B. Siklodi, A.B. Vogt, H. Kropshofer, F. Falcioni, M. Molina, D.R. Bolin, R. Campbell, G.J. Hammerling, and Z.A. Nagy Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells Hum. Immunol. 59 1998 463 471
43. M. Brandes, K. Willimann, and B. Moser Professional antigen-presentation function by human γδ T cells Science 309 2005 264 268
44. M. Brickelmaier, P.S. Hochman, R. Baciu, B. Chao, J.H. Cuervo, and A. Whitty ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-β J. Immunol. Methods 227 1999 121 135
45. F. Deisenhammer, M. Reindl, and T. Berger Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b J. Interferon Cytokine Res. 21 2001 167 171